National
Secret project seeks to advance pro-LGBT policy changes
Efforts are underway to start a new advocacy project that will work behind the scenes to facilitate pro-LGBT policy changes at the federal level and get LGBT people hired to key positions in the Obama administration.
According to an undated proposal obtained by DC Agenda, the group plans to aid the New Beginnings Initiative — a project led by the National Gay & Lesbian Task Force — and seeks to accelerate policy change within the administration this year while the Democrats control Congress.
The project has three main objectives: providing technical assistance for pro-LGBT policy changes in the Obama administration, ensuring LGBT people are represented in the federal government and advocating for an LGBT voice in the broader administration agenda.
A document outlining the project’s goals says the initiative “seeks no attribution for its role” and will work to provide the New Beginnings Initiative with “needed technical and strategic assistance as it works on many fronts, with many people, in a relatively short timeframe.”
The proposal emphasizes that change must come quickly while Democrats control Congress so hostile lawmakers don’t obstruct pro-LGBT changes by convening public hearings on the issues or otherwise being obstructionist.
“After November 2010 … these majorities are not guaranteed and the policy environment could become much more challenging,” says the document. “Therefore, it is essential that as much change as possible be achieved in the next 12 months.”
Organizers emphasize that “moving quickly is essential to the success of the project” for this year. Afterward, the initiative could be folded into other existing LGBT organizations, the document says.
“This project is designed to be a resource that can take on some of the functions and activities that are needed in the short-term to accomplish as much as possible in what could be a limited window of opportunity,” says the document. “In the long run, these functions, skills and experience should become part of existing LGBT organizations.”
A source familiar with the project, who spoke to DC Agenda on condition of anonymity, said the Gill Foundation and the Arcus Foundation are among donors to the new initiative.
Matt Foreman, a former head of the Task Force, is project director for the new organization, the source said. Foreman currently works as a program director for the Evelyn & Walter Haas, Jr. Fund. He didn’t immediately respond to DC Agenda’s request for comment on the new project.
The project’s budget is about $1.2 million for 2010, according to the documents obtained by DC Agenda. A considerable portion of the budget — about $650,000 — will be allotted for salaries for the staff, which will consist of the project director and three other staffers. Another $400,000 will be used to fund short-term consultants.
The source familiar with the new initiative called it “a done deal” and said it’s expected to launch officially around Feb. 1. Much of the initiative’s funding has already been allocated, the source said.
But the source questioned why this new initiative was necessary when other groups such as the Task Force, Human Rights Campaign and Gay & Lesbian Victory Fund already play similar roles.
“The folks at HRC — if you look at the federal advocacy piece of this — isn’t that just competition for them?” the source said. “Or if you look at the Victory Fund and them putting in [around 100 openly LGBT] people into positions in the Obama administration, and this plan has this whole thing about an appointments process — doesn’t that already exist somewhere in the community?”
The source called the new initiative “just an awful lot of duplication” and said “it seems strange” that donors would also fund this new initiative when other groups are doing similar work.
“The same foundations that fund all those really great organizations, and say really nice things about them, are now going to fund yet another organization that almost seems to compete with the organizations that currently exist,” said the source.
A Victory Fund spokesperson declined to comment on the new group. HRC and the Task Force didn’t respond to DC Agenda’s requests for comment.
The source also questioned why Foreman would be selected to lead a new initiative that is supposed to work behind the scenes. Foreman was an outspoken LGBT rights advocate while at the Task Force, particularly during the controversy over the proposed federal Employment Non-Discrimination Act in 2007. During that debate, he insisted on including gender identity language in the legislation.
“If they’re a behind-the-scenes, below-the-radar kind of project, you would think the person they would choose to run it would be kind of a quiet behind-the-scenes, low-key person — and that’s probably not Matt Foreman,” said the source.
The document outlining the new initiative details what needs to be accomplished for each of its three objectives. It says LGBT representation within federal committees, advisory councils and task forces is key to carrying out regulatory changes that would benefit LGBT people.
“Identifying and actively promoting LGBT and strong allied individuals to serve on these bodies will be a priority of this project, and our strategy will be a multi-tiered approach designed to change the culture at all levels of the federal government,” says the document.
The proposal gives particular attention to new bodies that would be created by pending health care reform legislation. Organizers note that the House bill would create a committee that would recommend health insurance minimums and enhanced benefits standards, and say the committee should “consider the concerns and health needs of the LGBT community and have LGBT representation on it.”
“The LGBT community should be ready with the names of primary care doctors (and others) who can be nominated to serve on this committee, as well as ready with a strategy for getting these individuals appointed,” says the document. “We are currently gathering names of potential LGBT committee members so that when health care reform passes, we can move quickly.”
A number of committees within the Department of Health & Human Services are cited as bodies for which organizers of the project are particularly seeking LGBT representation. The committees include the National Advisory Council on Nurse Education & Practice, the Advisory Committee on Research on Women’s Health and the Secretary’s Advisory Committee on Genetics, Health & Society.
The proposal says LGBT representation in HHS is particularly important because, among other reasons, it would help ensure that sexual health programs include LGBT issues, allocate resources for LGBT-specific prevention health needs and make sure LGBT seniors are supported in aging programs. Organizers are putting together a database of LGBT people who can serve on these committees and advisory groups, according to the document.
Another important objective for the new initiative is ensuring that LGBT voices are heard within the federal government as the Obama administration pursues its broader agenda.
“As the administration develops proposals to address other pressing domestic issues dealing with the economy, education, unemployment, etc., the LGBT community should be looking for opportunities to ensure that LGBT concerns in these areas are addressed and that LGBT individuals are looked to as a resource,” says the proposal.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Reasons to be optimistic about 2026
Using movement to boost your mental health during holidays
Reasons to be optimistic about 2026
America is going in the wrong direction for intersex children
Rush reopens after renewing suspended liquor license
Long-awaited ‘Pillion’ surpasses the sexy buzz
